No abstract

compare their clinico-biological characteristics and outcomes to classical variants.Methods: Individual data from patients enrolled in 5 studies were analysed, respectively RiPAD+C (Houot R. et al, Ann Oncol 2011), ABSTRACT difference in clinical features of survival but FFS was inferior in pleomorphic category.Frequently mutated genes in AH-MCL were ATM, CCND1, NOTCH1, KMT2D, KMT2C, TP53, SPEN, SMARCA4 and NSD2. There was no statistically significant difference in the mutation profile of dnMCL vs t-MCL. Significant differences in the mutation burden between pts with high Ki-67 (≥50%) and those with low Ki-67%, were noted -ATM (p = 0.001), CCND1 (p<0.001), NOTCH1(p = 0.001), TP53 (p = 0.006), SMARCA4 (p = 0.006), NSD2 (p = 0.02), NOTCH3(p = 0.02) Figure-1E. Conclusions:We have shown that pts with AH-MCL with t-MCL and/or Ki-67% ≥ 50% are a very high risk category of MCL. Further analysis are ongoing and will be reported.